Chávez-Ocaña S, Bravata-Alcántara JC, Acosta-Altamirano G, Reyes-Hernández O, Sierra-Martínez M

Language: Spanish
References: 29
Page: 155-164
PDF size: 202.21 Kb.

ABSTRACT

Introduction. For a decade EXIST evidence of the presence of circulating tumor cells (CTC) in Patients with Breast Cancer, this has been mainly linked a advanced stages and with a poor prognosis. Today it has been proposed to assess detection do effectiveness of society and treatment during any assess tumor recurrence, on bone marrow aspirate by RT-PCR. Recently reported the detection of this type of cells in peripheral blood by flow cytometry, which would have a quick method and cheaper, so that the purpose of this work was the search of CTC in peripheral blood by citometry with monoclonal antibody in women with breast cancer diagnosis and compared with the standards of diagnostic what is mammography and histopathology. Material and methods. A comparative, prospective and cross-sectional study was conducted. Peripheral blood of 42 patients who came first to the breast oncology clinic at the Hospital Juárez de México was obtained. The samples were processed and stained with a monoclonal antibody (CK19), the labeled cells were quantified by flow cytometry on a Bekton-Dickinson, the percentage of labeled cells cytometer and compared with the results of mammography and histopathology. Results. Using a test ANOVA single factor was found that there were significant differences in the percentages of cells labeled with CK19 among patients with benign tumors and those with malignant tumors, this being directly proportional difference to the stage of disease progression and mammography in advanced.

REFERENCES

1. Noriega Reyes MY, Langley McCarron E. Corrreguladores del receptor de estrógenos y su implicación en el cáncer mamario. Cancerología 2008; (3): 29-40.

2. Murray CJ, López AD. The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard University Press, Cambridge; 1996.

3. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression free and overall survival. Clin Cancer Res 2006; 12(14. Pt. 1): 4218-24.

4. Rodríguez-Cuevas S, Guisa-Hohenstein F, Labastida- Almendaro S. First breast cancer mammography screening program in Mexico: Initial results 2005-2006. Breast J 2009; 15(6): 623-31.

5. Liska V, Holubec L Jr, Treska V, Vrzalova J, Skalicky J, et al. Evaluation of tumour markers as differential diagnostic tool in patients with suspicion of liver metastases from breast cancer. Anticancer Res 2011; 31(4): 1447-51.

6. Rack B, Schindlbeck C, Jûckstock J, Andersgassen U, Hepp P, et al. Circulating tumor cells predict survival in early average-to high risk breast cancer patients. J Natl Cancer Inst 2014; 106(5).

7. Schweizer J, Bowden PE, Coulombe PA, Langblein L, Lane B, Magin TM, et al. New consensus nomenclature for mammalian keratins. J Cell Biol 2006; 174(2): 169-74

8. You F, Robers LA, Kang SP, Nunes RA, Dias C, Iglehart JD, et al. Low-Level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells. J Hematol Oncol 2008; 1: 2.

9. Markou A, Strati A, Malamos N, Georgoulias V, Lianidou ES. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clin Chem 2011; 57(3): 421-30.

10. Saloustros E, Mavroudis D. Cytokeratin 19-positive circulating tumor cells in early breast cancer prognosis. Future Oncol 2010; 6(2): 209-19.

11. Alix-Panabières C, Vendrell JP, Slijper M, Pelle O, Barbotte E, Mercier G, et al. Full length cytokeratin-19 released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res 2009; 11(3): R39

12. Fisher CS, Cole DJ, Mitas M, Garrett-Meyer E, Metcalf JS, Gillanders WE, et al. Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes fails to predict breast cancer recurrence: a final analysis of prospective multi-institutional cohort study. Ann Surg Oncol 2010; 17 (Suppl. 3): 312-20.

13. Chen Y, Zou TN, Wu ZP, Zhou YC, Gu YL, et al. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer. Int J Biol Markers 2010; 25(2): 59-68.

14. Huang SB, Bae JW, Lee HY, Kim Hy. Circulatin Tumor Cells Detected by RT-PCR for CK-20 before surgery indicate Worse Prognostic Impact in Triple-Negativa and HER Subtype Breast Cancer. J Breast Cancer 2012; 15(1): 34-42.

15. Zhao S, Liu Y, Zhang Q, Li H, Zhang M, Ma W, et al. The prognostic role of circulating tumor cells (CTCs) detected by RT-PCR in breast cancer: a meta-analysis of published literature. Breast Cancer Res Treat 2011; 130(3): 809-16.

16. Marrakchi R, Querhani S, Benammar S, Rouissi K, Bouhaha R, Bougatef K, et al. Detection of cytokeratin 19 mRNA and CYFRA21-1 (cytokeratin 19 fragments) in blood of Tunisian women with breast cancer. Int J Biol Markers 2008; 23(4): 238-43.

17. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 2009; 27(13): 2177-84.

18. Daslakati A, Angelaki S, Perraki M, Apostolaki S, Xenidis N, Stathopoulos E, Kontopodis E. Detection of citokeratin-19 mRNA positive cells in the peripheral blood and bone marrow patients with operable breast cancer. Br J Cancer 2009; 101(4); 589-97.

19. Effenberger KE, Borgen E, Eulenburg CZ, Bartkowiak K, Grosser A, Synnestved M, et al. Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern. Breast Cancer Res Treat 2011; 125(3): 729-38.

20. Wang L, Wang Y, Liu Y, Chang M, Wu Y, Wei H. Flow cytometric analisis of CK19 expression en the peripheral blood of breast carcinoma patients: relevance for circulating tumor cell detection. J Exp Clin Cancer Res 2009; 28: 57.

21. Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse trahscription-PCR assay for cytokeratin 19, mammaglobin and HER2 in early breast cancer. Clin Cancer Res 2008; 14(9): 2593-600.

22. Tjensvoll K, Oltedal S, Farmen RK, Shammas FV, Heikkilâ R, Kvaloey JT, et al. Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients. Clin Breast Cancer 2010; 10(5): 378-84.

23. Payne RE, Hava NL, Page K, Blighe K, Ward B, Slade M, Brown J, et al. The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy. Br J Cancer 2012; 106(2): 275-82.

24. Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ, et al. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from Metastatic Breast Cancer patients enrolled in North Central Treatment Group Trials, N0234/336/436/437. Clin Cancer Res 2012; 17(22); 7183-93

25. Sanisho L, Vertakova-Krakovska B, Kuliffay P, Brtko J, Galbava A, Galvavy S. Detection of circulating tumor cells in metastatic breast cancer patients. Endocr Regul 2011; 45(3): 113-24.

26. Visser M, Jiwa M, Horstman A, Brink AA, Pol RP, van Diest P, et al. Intra-operative rapid diagnostic method based on CK19 mRNA expression for the detection of lymph node metastases in breast cancer. Int J Cancer 2008; 122(11): 2562-7.

27. Kwon Y, Ro J, Kang HS, Kim Sk, Hong EK, Khang SK, et al. Clinicopathological parameters and biological markers predicting non-sentinel node metastasis in sentinel node-positive breast cancer patients. Oncol Rep 2011; 25(4): 1063-71.

28. Pujol JL, Grenier J, Daurès JP, Daver A, Pujol H, Michel FB. Serum fragments of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993; 53(1): 61-6.

29. Carrillo-González N, Ortuño-Sahagún D, Gudiño-Cabrera G. Expresión de las isoformas α y β del mRNA del GFAP durante la diferenciación de PNM de BO de rata adulta hacia el fenotipo de aldainoglía y en glía envolvente purificada. En: Avances en la Investigación Científica en el CUCBA. México, 2006; 267-73.